- Home
- GMED
GMED
Globus Medical Inc.
as 04-18-2025 1:36pm EST
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUDUBON |
| Market Cap: | N/A | IPO Year: | 2012 |
| Target Price: | $96.91 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.75 | EPS Growth: | -29.91 |
| 52 Week Low/High: | $49.33 - $94.93 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,519,355,000 | Revenue Growth: | 60.62% |
| Revenue Growth (this year): | 8.52% | Revenue Growth (next year): | 6.73% |
Stock Insider Trading Activity of Globus Medical Inc. (GMED)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RHOADS ANN D | GMED | Director | Feb 28 '25 | Sell | $78.68 | 7,500 | $590,100.00 | 35,384 |
Latest Globus Medical Inc. News
GMED Breaking Stock News: Dive into GMED Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Globus Medical Schedules First Quarter Earnings Release and Conference Call
Argus Research
3 days ago
GMED: Raising target price to $76.00
Simply Wall St.
4 days ago
Is The Market Rewarding Globus Medical, Inc. (NYSE:GMED) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Zacks
5 days ago
International Growth Drives GMED Stock Amid Fierce Competition
MT Newswires
8 days ago
Truist Trims Price Target on Globus Medical to $80 From $82, Keeps Hold Rating
StockStory
10 days ago
Medical Devices & Supplies - Specialty Stocks Q4 Teardown: Integer Holdings (NYSE:ITGR) Vs The Rest
Argus Research
10 days ago
GMED: Lowering target price to $72.00
Zacks
12 days ago
GMED Stock May Benefit Following the Acquisition of Nevro
Compare GMED vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMED Globus Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.